Literature DB >> 19949938

The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle.

Lin Piao1, Yong-Hu Fang, Virgilio J J Cadete, Christian Wietholt, Dalia Urboniene, Peter T Toth, Glenn Marsboom, Hannah J Zhang, Idith Haber, Jalees Rehman, Gary D Lopaschuk, Stephen L Archer.   

Abstract

Right ventricular hypertrophy (RVH) and RV failure contribute to morbidity and mortality in pulmonary arterial hypertension (PAH). The cause of RV dysfunction and the feasibility of therapeutically targeting the RV are uncertain. We hypothesized that RV dysfunction and electrical remodeling in RVH result, in part, from a glycolytic shift in the myocyte, caused by activation of pyruvate dehydrogenase kinase (PDK). We studied two complementary rat models: RVH + PAH (induced by monocrotaline) and RVH + without PAH (induced by pulmonary artery banding (PAB)). Monocrotaline RVH reduced RV O(2)-consumption and enhanced glycolysis. RV 2-fluoro-2-deoxy-glucose uptake, Glut-1 expression, and pyruvate dehydrogenase phosphorylation increased in monocrotaline RVH. The RV monophasic action potential duration and QT(c) interval were prolonged due to decreased expression of repolarizing voltage-gated K(+) channels (Kv1.5, Kv4.2). In the RV working heart model, the PDK inhibitor, dichloroacetate, acutely increased glucose oxidation and cardiac work in monocrotaline RVH. Chronic dichloroacetate therapy improved RV repolarization and RV function in vivo and in the RV Langendorff model. In PAB-induced RVH, a similar reduction in cardiac output and glycolytic shift occurred and it too improved with dichloroacetate. In PAB-RVH, the benefit of dichloroacetate on cardiac output was approximately 1/3 that in monocrotaline RVH. The larger effects in monocrotaline RVH likely reflect dichloroacetate's dual metabolic benefits in that model: regression of vascular disease and direct effects on the RV. Reduction in RV function and electrical remodeling in two models of RVH relevant to human disease (PAH and pulmonic stenosis) result, in part, from a PDK-mediated glycolytic shift in the RV. PDK inhibition partially restores RV function and regresses RVH by restoring RV repolarization and enhancing glucose oxidation. Recognition that a PDK-mediated metabolic shift contributes to contractile and ionic dysfunction in RVH offers insight into the pathophysiology and treatment of RVH.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19949938      PMCID: PMC3155251          DOI: 10.1007/s00109-009-0524-6

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  37 in total

1.  Action potential control of cardiac contractility.

Authors:  E H Wood
Journal:  Ann Biomed Eng       Date:  2000-08       Impact factor: 3.934

2.  Expression and regulation of pyruvate dehydrogenase kinase isoforms in the developing rat heart and in adulthood: role of thyroid hormone status and lipid supply.

Authors:  M C Sugden; M L Langdown; R A Harris; M J Holness
Journal:  Biochem J       Date:  2000-12-15       Impact factor: 3.857

3.  Dichloroacetate improves postischemic function of hypertrophied rat hearts.

Authors:  R B Wambolt; G D Lopaschuk; R W Brownsey; M F Allard
Journal:  J Am Coll Cardiol       Date:  2000-10       Impact factor: 24.094

Review 4.  Methodology for measuring in vitro/ex vivo cardiac energy metabolism.

Authors:  R L Barr; G D Lopaschuk
Journal:  J Pharmacol Toxicol Methods       Date:  2000 Mar-Apr       Impact factor: 1.950

5.  Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels.

Authors:  Evangelos D Michelakis; M Sean McMurtry; Xi-Chen Wu; Jason R B Dyck; Rohit Moudgil; Teresa A Hopkins; Gary D Lopaschuk; Lakshmi Puttagunta; Ross Waite; Stephen L Archer
Journal:  Circulation       Date:  2002-01-15       Impact factor: 29.690

6.  Downregulation of voltage-gated K(+) channels in rat heart with right ventricular hypertrophy.

Authors:  J K Lee; A Nishiyama; F Kambe; H Seo; S Takeuchi; K Kamiya; I Kodama; J Toyama
Journal:  Am J Physiol       Date:  1999-11

7.  Pyruvate dehydrogenase and the regulation of glucose oxidation in hypertrophied rat hearts.

Authors:  Carmen P Lydell; Andy Chan; Richard B Wambolt; Nandakumar Sambandam; Hannah Parsons; Gregory P Bondy; Brian Rodrigues; Kirill M Popov; Robert A Harris; Roger W Brownsey; Michael F Allard
Journal:  Cardiovasc Res       Date:  2002-03       Impact factor: 10.787

8.  Monophasic action potential recordings from intact mouse heart: validation, regional heterogeneity, and relation to refractoriness.

Authors:  B C Knollmann; A N Katchman; M R Franz
Journal:  J Cardiovasc Electrophysiol       Date:  2001-11

9.  Dynamic changes of gene expression in hypoxia-induced right ventricular hypertrophy.

Authors:  Saumya Sharma; Heinrich Taegtmeyer; Julia Adrogue; Peter Razeghi; Shiraj Sen; Kholiswa Ngumbela; M Faadiel Essop
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-11-20       Impact factor: 4.733

Review 10.  The long QT interval is not only inherited but is also linked to cardiac hypertrophy.

Authors:  Bernard Swynghedauw; Christophe Baillard; Paul Milliez
Journal:  J Mol Med (Berl)       Date:  2003-05-15       Impact factor: 4.599

View more
  138 in total

1.  Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension.

Authors:  Rubin M Tuder; Laura A Davis; Brian B Graham
Journal:  Am J Respir Crit Care Med       Date:  2011-11-10       Impact factor: 21.405

Review 2.  Pathobiology of pulmonary arterial hypertension and right ventricular failure.

Authors:  Norbert F Voelkel; Jose Gomez-Arroyo; Antonio Abbate; Harm J Bogaard; Mark R Nicolls
Journal:  Eur Respir J       Date:  2012-06-27       Impact factor: 16.671

Review 3.  Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies.

Authors:  Stephen L Archer; E Kenneth Weir; Martin R Wilkins
Journal:  Circulation       Date:  2010-05-11       Impact factor: 29.690

Review 4.  Redox biology in pulmonary arterial hypertension (2013 Grover Conference Series).

Authors:  Joshua P Fessel; James D West
Journal:  Pulm Circ       Date:  2015-12       Impact factor: 3.017

Review 5.  The right ventricle and pulmonary hypertension.

Authors:  Mariëlle C van de Veerdonk; Harm J Bogaard; Norbert F Voelkel
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

6.  Cyclophilin D controls mitochondrial pore-dependent Ca(2+) exchange, metabolic flexibility, and propensity for heart failure in mice.

Authors:  John W Elrod; Renee Wong; Shikha Mishra; Ronald J Vagnozzi; Bhuvana Sakthievel; Sanjeewa A Goonasekera; Jason Karch; Scott Gabel; John Farber; Thomas Force; Joan Heller Brown; Elizabeth Murphy; Jeffery D Molkentin
Journal:  J Clin Invest       Date:  2010-09-20       Impact factor: 14.808

7.  Ischemia-induced Drp1 and Fis1-mediated mitochondrial fission and right ventricular dysfunction in pulmonary hypertension.

Authors:  Lian Tian; Monica Neuber-Hess; Jeffrey Mewburn; Asish Dasgupta; Kimberly Dunham-Snary; Danchen Wu; Kuang-Hueih Chen; Zhigang Hong; Willard W Sharp; Shelby Kutty; Stephen L Archer
Journal:  J Mol Med (Berl)       Date:  2017-03-06       Impact factor: 4.599

Review 8.  Pulmonary arterial hypertension: pathogenesis and clinical management.

Authors:  Thenappan Thenappan; Mark L Ormiston; John J Ryan; Stephen L Archer
Journal:  BMJ       Date:  2018-03-14

9.  FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: therapeutic benefits of dichloroacetate.

Authors:  Lin Piao; Vaninder K Sidhu; Yong-Hu Fang; John J Ryan; Kishan S Parikh; Zhigang Hong; Peter T Toth; Erik Morrow; Shelby Kutty; Gary D Lopaschuk; Stephen L Archer
Journal:  J Mol Med (Berl)       Date:  2012-12-18       Impact factor: 4.599

Review 10.  Novel therapeutic approaches to preserve the right ventricle.

Authors:  Samar Farha; Erika L Lundgrin; Serpil C Erzurum
Journal:  Curr Heart Fail Rep       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.